SAN MATEO, Calif., Aug. 2, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced it has received an additional notice of allowance from the United States Patent and Trademark Office (USPTO) related to the company’s family of patents for NGX-1998, the Company’s next generation liquid formulation of prescription-strength capsaicin.
